𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma

✍ Scribed by Shinya Arinaga; Nobuya Karimine; Shigeru Nanbara; Hiroshi Inoue; Hideaki Nakashima; Hiroaki Ueo; Tsuyoshi Akiyoshi


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
635 KB
Volume
58
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Lymphokine-activated killer (LAK) cells generated by culture of regional lymph node cells (LNC) with interleukin 2 (IL 2) for 4 and 11 days were examined for their functional capabilities in comparison with those of peripheral blood mononuclear cells (PBM) in 25 patients with gastric carcinoma. The cytotoxic activity of LAK cells induced from LNC for 4-day culture with IL 2 was significantly lower than that from PBM. However, the LNC-LAK cytotoxicity was markedly increased up to almost the same level as that of PBM after l l-day culture. The production of interferon-? (INF-y) and tumor necrosis factor-a (TNF-a) from nonadherent LAK cells in LNC was also significantly reduced as compared to that from PBM 4 days after culture, when stimulated with or without tumor target, Raji cells. After 1 1-day culture with IL 2, however, the levels of these cytokines produced by LNC-LAK cells either with or without stimulation by tumor target were comparable to those by PBM-LAK cells, although the release of these cytokines was markedly reduced when compared to that after 4-day culture. Phenotypic analysis revealed decreased proportion of cells mediating NK activity in LNC before and 4 days after culture. CD56+ and CD57+ cells in LNC were increased after 11-day culture, although the percentages of these cells were still low as compared to those in PBM. The proportions of OKIal+ and CD25+ cells were uniformly increased after 4 and 11-day culture in both cell populations. Changes in subpopulations of CD4+ and CD8+ cells in LNC were not apparently different from PBM. These results indicated the differential LAK cell function of cells from regional lymph nodes from PBM in patients with gastric carcinoma.


πŸ“œ SIMILAR VOLUMES


Lymphokine-activated killer cell activit
✍ Nobuya Karimine; Shigeru Nanbara; Shinya Arinaga; Tsukasa Asoh; Hiroaki Ueo; Tsu πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 661 KB

Lymphokine-activated killer (LAK) cell activity of peripheral blood mononuclear cells (PBM), spleen cells (SPC), regional lymph node cells (LNC), and tumor-infiltrating lymphocytes (TIL), induced by activation with interleukin 2 (IL 2) for 4 days, was evaluated in patients with gastric carcinoma. TI

Defective function of lymphokine-activat
✍ Toshiji Saibara; Saburo Onishi; Hiroshi Sakaeda; Yasutake Yamamoto πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 608 KB

Lymphokine-activated killer activity and natural killer activity in hepatocellular carcinoma patients were d. Maximum lymphokine-activated killer activity was induced at 3 to 6 days of incubation, and lymphokine-activated killer activity tended to increase in a manner dose dependent of recombinant i

Antitumor activity of regional lymph nod
✍ Hidemichi Yaita; Kosei Yasumoto; Akira Nagashima; Keizo Sugimachi; Kikuo Nomoto πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 665 KB

Cytotoxic activities of regional lymph node lymphocytes (RLNL) and peripheral blood lymphocytes (PBL) of 49 primary lung cancer patients who were subjected to surgical resection were examined by 4 h 5'Cr release assay. PBL showed significantly lower cytotoxicity against autologous tumor cells than a

Neoadjuvant chemotherapy for patients wi
✍ Karen Becker; Umberto Fumagalli; James D. Mueller; Ulrich Fink; J. RΓΌdiger Siewe πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 135 KB πŸ‘ 2 views

## BACKGROUND. In a previous study the authors demonstrated, using immunohistochemical methods for epithelial antigens, that the regional lymph nodes of gastric adenocarcinoma contained individual tumor cells or small clusters of these cells (tumor cell microinvolvement [TCM]) in over 90% of cases